We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation (ACCESS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01007123
First Posted: November 3, 2009
Last Update Posted: March 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Albireo
  Purpose
The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with chronic idiopathic constipation.

Condition Intervention Phase
Constipation Chronic Constipation Drug: A3309 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of Elobixibat in Patients With Chronic Idiopathic Constipation

Resource links provided by NLM:


Further study details as provided by Albireo:

Primary Outcome Measures:
  • Change From Baseline in Frequency of Spontaneous Bowel Movements [ Time Frame: Baseline, weekly, up to 8 weeks ]
    Primary ep W 1


Secondary Outcome Measures:
  • Responder Analyses for Complete Spontaneous Bowel Movements (CSBMs) [ Time Frame: Baseline, weekly and up to 8 weeks ]

    A CSBM responder is defined as per FDA draft guidance for IBS-C:

    An increase of one or more of CSBMs per week over baseline for at least 4 out of the 8 weeks of treatment


  • Time to First Bowel Movement [ Time Frame: First week ]
  • Stool Consistency Change From Baseline [ Time Frame: Baseline, weekly and up to 8 weeks ]
    Bristol Stool Form Scale. Min value:1. Max value: 7. Higher value indicates more liquid shape than normal, lower indicates constipated state.

  • LDL/HDL Ratio [ Time Frame: Baseline and 8 weeks of treatment ]
    Ratio of plasma LDL cholesterol and HDL cholesterol Difference from baseline, placebo-adjusted

  • Straining Change From Baseline [ Time Frame: Baseline and during 8 weeks of treatment ]
    Daily assessment of straining. Min value: 1. Max value: 5. Higher value indicates more straining.


Enrollment: 190
Study Start Date: November 2009
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A3309 low dose
Administered once daily for the duration of the study
Drug: A3309
A3309 in three different dosage levels or placebo once daily for the duration of the study
Experimental: A3309 intermediate dose
Administered once daily for the duration of the study.
Drug: A3309
A3309 in three different dosage levels or placebo once daily for the duration of the study
Experimental: A3309 high dose
Administered once daily for the duration of the study
Drug: A3309
A3309 in three different dosage levels or placebo once daily for the duration of the study
Placebo Comparator: Placebo
Administered once daily for the duration of the study
Drug: A3309
A3309 in three different dosage levels or placebo once daily for the duration of the study

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient meets protocol specified criteria for constipation
  • Patient has successfully completed study requirements with no clinically relevant findings for physical exam, ECG, laboratory tests and colonoscopy as applicable

Exclusion Criteria:

  • Medical history or medical condition that would not make the patient a good candidate for the study or limit the patient´s ability to complete the study
  • Patient reports loose stools
  • Patient has IBS with pain/discomfort as predominant symptom
  • Patient needs medications prohibited as specified in the protocol
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01007123


  Show 44 Study Locations
Sponsors and Collaborators
Albireo
Investigators
Study Chair: Hans Graffner, MD Albireo
  More Information

Publications:
Responsible Party: Albireo
ClinicalTrials.gov Identifier: NCT01007123     History of Changes
Other Study ID Numbers: A3309-002
First Submitted: November 2, 2009
First Posted: November 3, 2009
Results First Submitted: November 1, 2016
Results First Posted: March 22, 2017
Last Update Posted: March 22, 2017
Last Verified: February 2017

Keywords provided by Albireo:
Chronic idiopathic constipation
A3309

Additional relevant MeSH terms:
Constipation
Signs and Symptoms, Digestive
Signs and Symptoms


To Top